Part 9/10:
Currently, the most significant limitation is the absence of large-scale clinical trials confirming efficacy and safety in humans. However, a promising trial is officially in progress, which could further validate these strategies.
Moreover, understanding the genetic landscape of individual tumors, particularly the KRAS mutation, is key to tailoring such treatments effectively. As research advances, personalized approaches combining diet, high-dose vitamins, and conventional therapies might revolutionize cancer management, especially for stubborn mutation-driven cancers.